Recent Updates — SRXH
SRX Global Inc. entered into a Stock Purchase Agreement to acquire all outstanding capital stock of CERo Therapeutics, Inc., the wholly owned subsidiary of CERo Therapeutics Holdings, Inc. At closing, SRX will issue shares valued at $1 million based on the lower of the prior day's closing price or 20-day VWAP, forgive up to $11.7 million in principal under a Consolidated Senior Secured Promissory Note, and assume approximately $1.6 million in liabilities. The transaction includes a 30-day go-shop period allowing Holdings to solicit superior proposals, with reciprocal $750,000 termination fees. Closing is conditioned on the acquisition of Holdings' preferred stock and necessary consents. SRX Global Inc. operates in the healthcare sector.
SRX Global Inc. announced a $1.5 million commitment to launch a new family of actively managed exchange-traded funds through its EMJX platform, in partnership with Kupa Inc. The initial fund will feature an actively managed digital asset hedging strategy powered by proprietary AI technology and is expected to be available to investors in the first quarter of 2027. SRX intends to distribute dividends from the ETF holdings directly to shareholders, though specific timing and record dates have not yet been determined. SRX Global Inc. operates as an AI-enabled platform focused on generating shareholder value through investments in operating companies and strategic assets.
SRX Global Inc. completed a secured financing transaction with CERo Therapeutics Holdings, Inc., issuing a Consolidated Senior Secured Promissory Note aggregating $5,666,108.77 to consolidate previous convertible notes. The agreement allows for additional advances up to $6,000,000, bringing the maximum loan facility to $11,666,108.77. An initial advance of $775,665.00 was funded on August 27, 2026, with monthly funding scheduled thereafter based on CERO's budget. The debt bears interest at 10% per annum and matures on October 15, 2026, secured by CERO’s subsidiary stock and assets. SRX Global Inc. operates as an AI-enabled investment platform focused on generating shareholder value through strategic investments in operating companies.
SRX Global Inc. entered into a Securities Purchase Agreement on August 27, 2026, selling 3,579 shares of Series C convertible preferred stock to accredited investors for $2,862,500. The purchase price was satisfied by the assignment of Convertible Grid Promissory Notes from CERO Therapeutics Holdings with an aggregate principal amount of $2,812,500. Each share has a stated value of $1,000 and converts at a fixed price of $2.1888 per share into common stock. The company also entered a Registration Rights Agreement to register the resale of shares issuable upon conversion and warrant exercise. SRX Global Inc. operates in the biotechnology sector.
SRX Global Inc. reported fiscal third quarter results ended June 30, 2026, with net sales of $3.4 million and a net loss from continuing operations of $4.1 million. The company completed the acquisition of EMJX on June 16, 2026, an AI-enabled digital-asset treasury platform. It declared a one-time cash dividend of $0.05 per share to shareholders of record on July 22, 2026. Net asset value was reported at $62.9 million, or $3.22 per common share, following a one-for-sixty reverse stock split effective July 6, 2026. The company also approved a $10 million share repurchase program and ended the quarter with $36.7 million in cash and no debt outstanding. SRX Global Inc. operates as an investment holding company focused on AI-enabled platforms and strategic assets.